{"protocolSection":{"identificationModule":{"nctId":"NCT04588480","orgStudyIdInfo":{"id":"C4591005"},"organization":{"fullName":"BioNTech SE","class":"INDUSTRY"},"briefTitle":"Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults","officialTitle":"A PHASE 1/2, PLACEBO-CONTROLLED, RANDOMIZED, AND OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A SARS-COV-2 RNA VACCINE CANDIDATE AGAINST COVID-19 IN HEALTHY JAPANESE ADULTS"},"statusModule":{"statusVerifiedDate":"2023-01","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2020-10-21","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2021-11-25","type":"ACTUAL"},"completionDateStruct":{"date":"2021-11-25","type":"ACTUAL"},"studyFirstSubmitDate":"2020-10-14","studyFirstSubmitQcDate":"2020-10-14","studyFirstPostDateStruct":{"date":"2020-10-19","type":"ACTUAL"},"resultsFirstSubmitDate":"2022-11-23","resultsFirstSubmitQcDate":"2023-01-13","resultsFirstPostDateStruct":{"date":"2023-02-01","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-01-13","lastUpdatePostDateStruct":{"date":"2023-02-01","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"BioNTech SE","class":"INDUSTRY"},"collaborators":[{"name":"Pfizer","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":true},"descriptionModule":{"briefSummary":"This is a Phase 1/2, randomized, placebo-controlled, and observer-blind study in healthy Japanese adults.\n\nThe study will evaluate the safety, tolerability, and immunogenicity of the SARS-CoV-2 RNA vaccine candidate against COVID-19:\n\n* As 2 doses, separated by 21 days\n* At a single dose level\n* In adults 20 to 85 years of age","detailedDescription":"From protocol amendment 3, this study is transitioned from a clinical trial to a postmarketing study (Phase 4) according to the Japanese regulation, because BNT162b2 was approved by the Ministry of Health, Labour and Welfare on 14 February 2021."},"conditionsModule":{"conditions":["SARS-CoV-2 Infection","COVID-19"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":160,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"BNT162b2","type":"EXPERIMENTAL","description":"BNT162b2 (intramuscular injection)","interventionNames":["Biological: BNT162b2"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Placebo (intramuscular injection)","interventionNames":["Other: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"BNT162b2","description":"BNT162b2 (intramuscular injection)","armGroupLabels":["BNT162b2"]},{"type":"OTHER","name":"Placebo","description":"Placebo (intramuscular injection)","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Participants With Local Reactions by Maximum Severity Within 7 Days After Dose 1","description":"Local reactions included pain at injection site, redness and swelling and were recorded by participants in an electronic diary (e-diary). Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 centimeter (cm) and graded as mild: greater than (\\>) 2.0 to 5.0 cm, moderate: \\>5.0 to 10.0 cm, severe: \\>10.0 cm, grade 4 (potentially life threatening): necrosis or exfoliative dermatitis for redness and necrosis for swelling. Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfered with daily activity, severe: prevented daily activity and grade 4 (potentially life threatening): emergency room visit or hospitalization for severe pain. Events were classified as Grade 4 based on study investigator's judgement. Maximum severity was the highest grade within 7 days after vaccination among severity grades where the answers were neither \"no\" nor missing for at least 1 day.","timeFrame":"Within 7 days after Dose 1"},{"measure":"Percentage of Participants With Local Reactions by Maximum Severity Within 7 Days After Dose 2","description":"Local reactions included pain at injection site, redness and swelling and were recorded by participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm and graded as mild: \\> 2.0 to 5.0 cm, moderate: \\>5.0 to 10.0 cm, severe: \\>10.0 cm, grade 4 (potentially life threatening): necrosis or exfoliative dermatitis for redness and necrosis for swelling. Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfered with daily activity, severe: prevented daily activity and grade 4 (potentially life threatening): emergency room visit or hospitalization for severe pain. Events were classified as Grade 4 based on study investigator's judgement. Maximum severity was the highest grade within 7 days after vaccination among severity grades where the answers were neither \"no\" nor missing for at least 1 day.","timeFrame":"Within 7 days after Dose 2"},{"measure":"Percentage of Participants With Systemic Events by Maximum Severity Within 7 Days After Dose 1","description":"Systemic events were recorded by participants in e-diary. Fever was categorized as greater than or equal to (\\>=)37.5 to 38.4 degrees(deg) Celsius(C), \\>38.4 to 38.9 deg C, \\>38.9 to 40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain were graded as mild: did not interfere with activity, moderate: some interference with activity and severe: prevented daily routine activity. Vomiting was graded as mild: 1 to 2 times in 24 hours(h), moderate: \\>2 times in 24h and severe: required intravenous hydration. Diarrhea was graded as mild: 2 to 3 loose stools in 24h, moderate: 4 to 5 loose stools in 24h and severe: 6 or more loose stools in 24h. Events were classified as Grade 4 potentially life threatening (emergency room visit or hospitalization) based on study investigator's judgement. Maximum severity=highest grade within 7 days after vaccination among severity grades where the answers were neither \"no\" nor missing for at least 1 day.","timeFrame":"Within 7 days after Dose 1"},{"measure":"Percentage of Participants With Systemic Events by Maximum Severity Within 7 Days After Dose 2","description":"Systemic events were recorded by participants in an e-diary. Fever was categorized as \\>= 37.5 to 38.4 deg C, \\>38.4 to 38.9 deg C, \\>38.9 to 40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain were graded as mild: did not interfere with activity, moderate: some interference with activity and severe: prevented daily routine activity. Vomiting was graded as mild: 1 to 2 times in 24h, moderate: \\>2 times in 24h and severe: required intravenous hydration. Diarrhea was graded as mild: 2 to 3 loose stools in 24h, moderate: 4 to 5 loose stools in 24h and severe: 6 or more loose stools in 24h. Events were classified as Grade 4 potentially life threatening (emergency room visit or hospitalization) based on study investigator's judgement. Maximum severity=highest grade within 7 days after vaccination among severity grades where the answers were neither \"no\" nor missing for at least 1 day.","timeFrame":"Within 7 days after Dose 2"},{"measure":"Percentage of Participants With Adverse Events (AEs) From Dose 1 up to 1 Month After Dose 2","description":"An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants with AEs and the associated 95% confidence interval (CI) based on the Clopper and Pearson method was presented. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.","timeFrame":"Dose 1 up to 1 month after Dose 2"},{"measure":"Percentage of Participants With Serious Adverse Events (SAEs) From Dose 1 up to 12 Months After Dose 2","description":"SAE was defined as any untoward medical occurrence that, at any dose, resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect or considered an important medical event. Percentage of participants with SAEs and the associated 95% CI based on the Clopper and Pearson method was presented.","timeFrame":"Dose 1 up to 12 months after Dose 2"},{"measure":"Percentage of Participants With Abnormal Hematology and Chemistry Laboratory Values 1 Day After Dose 1 by Age Category","description":"The pre-defined criteria for laboratory parameters included: hemoglobin (HGB), hematocrit, erythrocytes(ery.) less than (\\<)0.8\\* lower limit of normal (LLN); ery. mean corpuscular volume, ery. mean corpuscular hemoglobin, ery. mean corpuscular HGB concentration \\<0.9\\*LLN and \\>1.1\\*upper limit of normal (ULN); platelets \\<0.5\\*LLN and \\>1.75\\*ULN; leukocytes \\<0.6\\*LLN and \\>1.5\\*ULN; lymphocytes, neutrophils \\<0.8\\*LLN and \\>1.2\\*ULN; basophils, eosinophils, monocytes \\>1.2\\*ULN; bilirubin \\>1.5\\*ULN; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase \\>3.0\\*ULN; urea nitrogen, creatinine \\>1.3\\*ULN. Percentage of participants with abnormal hematology and chemistry laboratory values by age categories 20 to 64 years and 65 to 85 years were reported in this outcome measure. Categories with at least 1 non-zero data values were reported.","timeFrame":"Within 1 day after Dose 1"},{"measure":"Percentage of Participants With Abnormal Hematology and Chemistry Laboratory Values 7 Days After Dose 1 by Age Category","description":"The pre-defined criteria for laboratory parameters included: HGB, hematocrit, ery. \\<0.8\\* LLN; ery. mean corpuscular volume, ery. mean corpuscular hemoglobin, ery. mean corpuscular HGB concentration \\<0.9\\*LLN and \\>1.1\\*ULN; platelets \\<0.5\\*LLN and \\>1.75\\*ULN; leukocytes \\<0.6\\*LLN and \\>1.5\\*ULN; lymphocytes, neutrophils \\<0.8\\*LLN and \\>1.2\\*ULN; basophils, eosinophils, monocytes \\>1.2\\*ULN; bilirubin \\>1.5\\*ULN; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase \\>3.0\\*ULN; urea nitrogen, creatinine \\>1.3\\*ULN. Percentage of participants with abnormal hematology and chemistry laboratory values by age categories 20 to 64 years and 65 to 85 years were reported in this outcome measure. Categories with at least 1 non-zero data values were reported.","timeFrame":"Within 7 days after Dose 1"},{"measure":"Percentage of Participants With Abnormal Hematology and Chemistry Laboratory Values 7 Days After Dose 2 by Age Category","description":"The pre-defined criteria for laboratory parameters included: HGB, hematocrit, ery. \\<0.8\\* LLN; ery. mean corpuscular volume, ery. mean corpuscular hemoglobin, ery. mean corpuscular HGB concentration \\<0.9\\*LLN and \\>1.1\\*ULN; platelets \\<0.5\\*LLN and \\>1.75\\*ULN; leukocytes \\<0.6\\*LLN and \\>1.5\\*ULN; lymphocytes, neutrophils \\<0.8\\*LLN and \\>1.2\\*ULN; basophils, eosinophils, monocytes \\>1.2\\*ULN; bilirubin \\>1.5\\*ULN; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase \\>3.0\\*ULN; urea nitrogen, creatinine \\>1.3\\*ULN. Categories with at least 1 non-zero data value were reported (only 65-85 years: Lymphocytes category was reported).","timeFrame":"Within 7 days after Dose 2"},{"measure":"Percentage of Participants With Shift in Hematology and Chemistry Laboratory Values From Baseline to 1 Day After Dose 1 by Age Category","description":"Hematology parameters: hemoglobin, eosinophils, lymphocytes decrease, neutrophil decrease, platelets decrease, white blood cell (WBC) decrease, WBC increase. Chemistry parameters: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, bilirubin increased, creatinine increased, blood urea nitrogen. Laboratory abnormalities were graded by toxicity grading scale for healthy adult volunteers enrolled in preventive vaccine clinical trials as grade 1=mild; grade 2=moderate; grade 3=severe and grade 4=potentially life-threatening. Percentage of participants with shift in hematology and chemistry laboratory values by age categories (20 to 64 years and 65 to 85 years) were reported in this outcome measure. Categories with at least 1 non-zero data values showing any shift in Grade from baseline to 1 day after dose 1 (post-baseline) were reported. Participants whose grade category was unchanged (e.g. normal to normal) were not reported.","timeFrame":"From baseline (observation prior to Dose 1) up to 1 day after Dose 1"},{"measure":"Percentage of Participants With Shift in Hematology and Chemistry Laboratory Values From Baseline to 7 Days After Dose 1 by Age Category","description":"Hematology parameters included: hemoglobin, eosinophils, lymphocytes decrease, neutrophil decrease, platelets decrease, WBC decrease, WBC increase. Chemistry parameters included: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, bilirubin increased, creatinine increased, urea nitrogen. Laboratory abnormalities were graded by toxicity grading scale for healthy adult volunteers enrolled in preventive vaccine clinical trials as grade 1=mild; grade 2=moderate; grade 3=severe and grade 4=potentially life-threatening. Percentage of participants with shift in hematology and chemistry laboratory values by age categories (20 to 64 years and 65 to 85 years) were reported in this outcome measure. Categories with at least 1 non-zero data values showing any shift in grade from baseline to 7 days after dose 1 (post-baseline) were reported. Participants whose grade category was unchanged (e.g. normal to normal) were not reported.","timeFrame":"From baseline (observation prior to Dose 1) up to 7 days after Dose 1"},{"measure":"Percentage of Participants With Shift in Hematology and Chemistry Laboratory Values From Before Dose 2 to 7 Days After Dose 2 by Age Category","description":"Hematology parameters included: hemoglobin, eosinophils, lymphocytes decrease, neutrophil decrease, platelets decrease, WBC decrease, WBC increase. Chemistry parameters included: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, bilirubin increased, creatinine increased, urea nitrogen. Laboratory abnormalities were graded by toxicity grading scale for healthy adult volunteers enrolled in preventive vaccine clinical trials as grade 1=mild; grade 2=moderate; grade 3= severe and grade 4=potentially life-threatening. Percentage of participants with shift in hematology and chemistry laboratory values by age categories (20 to 64 years and 65 to 85 years) were reported in this outcome measure. Categories with at least 1 non-zero data values showing any shift in grade from before dose 2 to 7 days after dose 2 were reported. Participants whose grade category was unchanged (e.g. normal to normal) were not reported.","timeFrame":"Before Dose 2 up to 7 days after Dose 2"},{"measure":"Geometric Mean Titers (GMTs) of SARS-CoV-2 Neutralizing Titers at 1 Month After Dose 2","description":"GMT of SARS-CoV-2 neutralizing titer was calculated by exponentiating the mean logarithm of the titers and the corresponding 95% confidence interval (CI) was based on the Student's t distribution. GMT of SARS-CoV-2 neutralization titer 50% (NT50) was reported in this outcome measure.","timeFrame":"1 month after Dose 2"},{"measure":"Geometric Mean Fold Rises (GMFRs) of SARS-CoV-2 Neutralizing Titers From Before Vaccination to 1 Month After Dose 2","description":"GMFR was defined as the result after vaccination divided by the result before vaccination. GMFR and the corresponding 2-sided 95% CIs was calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student's t distribution). GMFR of SARS-CoV-2 NT50 was reported in this outcome measure.","timeFrame":"Before vaccination up to 1 month after Dose 2"}],"secondaryOutcomes":[{"measure":"GMTs of SARS-CoV-2 Neutralizing Titers at Baseline, 21 Days After Dose 1; 7 and 14 Days and 6 and 12 Months After Dose 2","description":"GMTs of SARS-CoV-2 neutralizing titers were calculated by exponentiating the mean logarithm of the titers and the corresponding 95% CI was based on the Student's t distribution. GMTs of SARS-CoV-2 NT50 and neutralization titer 90% (NT90) were reported in this outcome measure.","timeFrame":"NT50: Baseline (observation prior to Dose 1), 21 days after Dose 1; 7 and 14 days and 6 and 12 months after Dose 2; NT90: Baseline (observation prior to Dose 1), 21 days after Dose 1; 7 and 14 days after Dose 2"},{"measure":"GMFRs of SARS-CoV-2 Neutralizing Titers Before Vaccination to 21 Days After Dose 1; 7 and 14 Days and 6 and 12 Months After Dose 2","description":"GMFR was defined as the result after vaccination divided by the result before vaccination. GMFRs and the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student's t distribution). GMFRs of SARS-CoV-2 NT50 and NT90 were reported in this outcome measure.","timeFrame":"NT50: Before vaccination up to 21 days after Dose 1; 7 and 14 days and 6 and 12 months after Dose 2; NT90: Before vaccination up to 21 days after Dose 1; 7 and 14 days after Dose 2"},{"measure":"GMTs of SARS-CoV-2 Neutralizing Titers at Baseline, 21 Days After Dose 1; 7 and 14 Days and 1, 6 and 12 Months After Dose 2 in Participants With or Without Confirmed COVID-19 Before Dose 2","description":"GMTs of SARS-CoV-2 neutralizing titers was planned to be calculated by exponentiating the mean logarithm of the titers and the corresponding 95% CI was based on the Student's t distribution.","timeFrame":"Baseline (observation prior to Dose 1), 21 days after Dose 1; 7 and 14 days and 1, 6 and 12 months after Dose 2"},{"measure":"GMFRs of SARS-CoV-2 Neutralizing Titers Before Vaccination to 21 Days After Dose 1; 7 and 14 Days and 1, 6 and 12 Months After Dose 2 in Participants With or Without Confirmed COVID-19 Before Dose 2","description":"GMFR was defined as the result after vaccination divided by the result before vaccination. GMFRs and the corresponding 2-sided 95% CIs were planned to be calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student's t distribution).","timeFrame":"Before vaccination up to 21 days after Dose 1; 7 and 14 days after Dose 2 and 1, 6 and 12 months after Dose 2"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Japanese male or female participants between the ages of 20 and 85 years, inclusive, at randomization.\n* Participants who are willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, and other study procedures.\n* Healthy participants who are determined by medical history, physical examination, and clinical judgment of the investigator to be eligible for inclusion in the study.\n* Capable of giving personal signed informed consent.\n\nExclusion Criteria:\n\n* Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.\n* Known infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV).\n* History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s).\n* Receipt of medications intended to prevent COVID-19.\n* Previous confirmed diagnosis of COVID-19.\n* Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.\n* Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.\n* Women who are pregnant or breastfeeding.\n* Previous vaccination with any coronavirus vaccine.\n* Individuals who receive treatment with immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or planned receipt throughout the study.\n* Receipt of blood/plasma products or immunoglobulin, from 60 days before study intervention administration or planned receipt throughout the study.\n* Participation in other studies involving study intervention within 28 days prior to study entry and/or during study participation.\n* Previous participation in other studies involving study intervention containing lipid nanoparticles.\n* Subset only: Any screening hematology and/or blood chemistry laboratory value that meets the definition of a ≥ Grade 1 abnormality.\n* Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.","healthyVolunteers":true,"sex":"ALL","minimumAge":"20 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Pfizer CT.gov Call Center","affiliation":"Pfizer","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"SOUSEIKAI Sumida Hospital","city":"Sumida-ku","state":"Tokyo","zip":"130-0004","country":"Japan"},{"facility":"SOUSEIKAI PS Clinic","city":"Fukuoka","zip":"812-0025","country":"Japan","geoPoint":{"lat":33.6,"lon":130.41667}}]},"referencesModule":{"references":[{"pmid":"34907170","type":"DERIVED","citation":"Haranaka M, Baber J, Ogama Y, Yamaji M, Aizawa M, Kogawara O, Scully I, Lagkadinou E, Tureci Ӧ, Sahin U, Dormitzer PR, Gruber WC, Lockhart S. A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults. Nat Commun. 2021 Dec 14;12(1):7105. doi: 10.1038/s41467-021-27316-2."}],"seeAlsoLinks":[{"label":"To obtain contact information for a study center near you, click here.","url":"https://pmiform.com/clinical-trial-info-request?StudyID=C4591005"}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Originally, study was blinded and participants received 2 doses of ribonucleic acid (RNA)-based COVID-19 vaccine (BNT162b2) and placebo. After protocol amendment 3, the study was unblinded and all participants who originally received placebo were offered the opportunity to receive BNT162b2 vaccine before the 6-month follow-up visit.","groups":[{"id":"FG000","title":"BNT162b2","description":"Participants received 2 doses of blinded 30 microgram (mcg) BNT162b2 vaccine as an intramuscular injection separated by 21 days. Participants were followed up to 12 months after last dose of vaccination."},{"id":"FG001","title":"Placebo","description":"Participants received 2 doses of placebo (normal sterile saline solution) as an intramuscular injection separated by 21 days. Participants were followed up to 12 months after last dose of vaccination."},{"id":"FG002","title":"Placebo Then BNT162b2","description":"Participants who originally received 2 doses of blinded placebo were administered 2 doses of 30 mcg BNT162b2 vaccine as intramuscular injection separated by 21 days after unblinding. Participants were followed for up to 6 months after last dose of vaccination."}],"periods":[{"title":"Blinded Phase: Up to 6 Months","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"119"},{"groupId":"FG001","numSubjects":"41"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"119"},{"groupId":"FG001","numSubjects":"41"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]}]},{"title":"Unblinded Phase: From 6 to 12 Months","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"119"},{"groupId":"FG001","comment":"Participants who declined BNT162b2 30 mcg after unblinding.","numSubjects":"6"},{"groupId":"FG002","numSubjects":"35"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"117"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"35"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Safety population included all randomized participants who received at least 1 dose of the study intervention.","groups":[{"id":"BG000","title":"BNT162b2","description":"Participants received 2 doses of blinded 30 mcg BNT162b2 vaccine as an intramuscular injection separated by 21 days. Participants were followed up to 12 months after last dose of vaccination."},{"id":"BG001","title":"Placebo","description":"Participants received 2 doses of placebo (normal sterile saline solution) as an intramuscular injection separated by 21 days. Participants were followed up to 12 months after last dose of vaccination."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"119"},{"groupId":"BG001","value":"41"},{"groupId":"BG002","value":"160"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"46.8","spread":"16.16"},{"groupId":"BG001","value":"44.8","spread":"17.76"},{"groupId":"BG002","value":"46.3","spread":"16.55"}]}]}]},{"title":"Age, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"20-64 Years","measurements":[{"groupId":"BG000","value":"97"},{"groupId":"BG001","value":"33"},{"groupId":"BG002","value":"130"}]},{"title":"65-85 Years","measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"30"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"60"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"79"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"59"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"81"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"119"},{"groupId":"BG001","value":"41"},{"groupId":"BG002","value":"160"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"119"},{"groupId":"BG001","value":"41"},{"groupId":"BG002","value":"160"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Local Reactions by Maximum Severity Within 7 Days After Dose 1","description":"Local reactions included pain at injection site, redness and swelling and were recorded by participants in an electronic diary (e-diary). Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 centimeter (cm) and graded as mild: greater than (\\>) 2.0 to 5.0 cm, moderate: \\>5.0 to 10.0 cm, severe: \\>10.0 cm, grade 4 (potentially life threatening): necrosis or exfoliative dermatitis for redness and necrosis for swelling. Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfered with daily activity, severe: prevented daily activity and grade 4 (potentially life threatening): emergency room visit or hospitalization for severe pain. Events were classified as Grade 4 based on study investigator's judgement. Maximum severity was the highest grade within 7 days after vaccination among severity grades where the answers were neither \"no\" nor missing for at least 1 day.","populationDescription":"Safety population included all randomized participants who received at least 1 dose of the study intervention.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Within 7 days after Dose 1","groups":[{"id":"OG000","title":"BNT162b2","description":"Participants received 2 doses of blinded 30 mcg BNT162b2 vaccine as an intramuscular injection separated by 21 days. Participants were followed up to 12 months after last dose of vaccination."},{"id":"OG001","title":"Placebo","description":"Participants received 2 doses of placebo (normal sterile saline solution) as an intramuscular injection separated by 21 days. Participants were followed up to 12 months after last dose of vaccination."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"41"}]}],"classes":[{"title":"Redness: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"7.6","lowerLimit":"3.5","upperLimit":"13.9"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Redness: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"5.9","lowerLimit":"2.4","upperLimit":"11.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Redness: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"3.1"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Redness: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"3.1"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Swelling: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"9.2","lowerLimit":"4.7","upperLimit":"15.9"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Swelling: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"3.4","lowerLimit":"0.9","upperLimit":"8.4"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Swelling: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"3.1"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Swelling: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"3.1"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Pain at the injection site: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"57.1","lowerLimit":"47.7","upperLimit":"66.2"},{"groupId":"OG001","value":"2.4","lowerLimit":"0.1","upperLimit":"12.9"}]}]},{"title":"Pain at the injection site: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"27.7","lowerLimit":"19.9","upperLimit":"36.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Pain at the injection site: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"1.7","lowerLimit":"0.2","upperLimit":"5.9"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Pain at the injection site: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"3.1"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Local Reactions by Maximum Severity Within 7 Days After Dose 2","description":"Local reactions included pain at injection site, redness and swelling and were recorded by participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm and graded as mild: \\> 2.0 to 5.0 cm, moderate: \\>5.0 to 10.0 cm, severe: \\>10.0 cm, grade 4 (potentially life threatening): necrosis or exfoliative dermatitis for redness and necrosis for swelling. Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfered with daily activity, severe: prevented daily activity and grade 4 (potentially life threatening): emergency room visit or hospitalization for severe pain. Events were classified as Grade 4 based on study investigator's judgement. Maximum severity was the highest grade within 7 days after vaccination among severity grades where the answers were neither \"no\" nor missing for at least 1 day.","populationDescription":"Safety population included all randomized participants who received at least 1 dose of the study intervention. Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Within 7 days after Dose 2","groups":[{"id":"OG000","title":"BNT162b2","description":"Participants received 2 doses of blinded 30 mcg BNT162b2 vaccine as an intramuscular injection separated by 21 days. Participants were followed up to 12 months after last dose of vaccination."},{"id":"OG001","title":"Placebo","description":"Participants received 2 doses of placebo (normal sterile saline solution) as an intramuscular injection separated by 21 days. Participants were followed up to 12 months after last dose of vaccination."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"116"},{"groupId":"OG001","value":"41"}]}],"classes":[{"title":"Redness: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"6.0","lowerLimit":"2.5","upperLimit":"12.0"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Redness: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"4.3","lowerLimit":"1.4","upperLimit":"9.8"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Redness: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"3.1"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Redness: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"3.1"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Swelling: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"4.3","lowerLimit":"1.4","upperLimit":"9.8"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Swelling: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"4.3","lowerLimit":"1.4","upperLimit":"9.8"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Swelling: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"3.1"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Swelling: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"3.1"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Pain at the injection site: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"50.9","lowerLimit":"41.4","upperLimit":"60.3"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Pain at the injection site: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"26.7","lowerLimit":"18.9","upperLimit":"35.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Pain at the injection site: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"1.7","lowerLimit":"0.2","upperLimit":"6.1"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Pain at the injection site: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"3.1"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Systemic Events by Maximum Severity Within 7 Days After Dose 1","description":"Systemic events were recorded by participants in e-diary. Fever was categorized as greater than or equal to (\\>=)37.5 to 38.4 degrees(deg) Celsius(C), \\>38.4 to 38.9 deg C, \\>38.9 to 40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain were graded as mild: did not interfere with activity, moderate: some interference with activity and severe: prevented daily routine activity. Vomiting was graded as mild: 1 to 2 times in 24 hours(h), moderate: \\>2 times in 24h and severe: required intravenous hydration. Diarrhea was graded as mild: 2 to 3 loose stools in 24h, moderate: 4 to 5 loose stools in 24h and severe: 6 or more loose stools in 24h. Events were classified as Grade 4 potentially life threatening (emergency room visit or hospitalization) based on study investigator's judgement. Maximum severity=highest grade within 7 days after vaccination among severity grades where the answers were neither \"no\" nor missing for at least 1 day.","populationDescription":"Safety population included all randomized participants who received at least 1 dose of the study intervention.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Within 7 days after Dose 1","groups":[{"id":"OG000","title":"BNT162b2","description":"Participants received 2 doses of blinded 30 mcg BNT162b2 vaccine as an intramuscular injection separated by 21 days. Participants were followed up to 12 months after last dose of vaccination."},{"id":"OG001","title":"Placebo","description":"Participants received 2 doses of placebo (normal sterile saline solution) as an intramuscular injection separated by 21 days. Participants were followed up to 12 months after last dose of vaccination."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"41"}]}],"classes":[{"title":"Fever: >= 37.5 to 38.4 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"11.8","lowerLimit":"6.6","upperLimit":"19.0"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Fever: >38.4 to 38.9 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"2.5","lowerLimit":"0.5","upperLimit":"7.2"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Fever: >38.9 to 40.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"3.1"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Fever: >40.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"3.1"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Fatigue: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"22.7","lowerLimit":"15.5","upperLimit":"31.3"},{"groupId":"OG001","value":"7.3","lowerLimit":"1.5","upperLimit":"19.9"}]}]},{"title":"Fatigue: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"16.8","lowerLimit":"10.6","upperLimit":"24.8"},{"groupId":"OG001","value":"2.4","lowerLimit":"0.1","upperLimit":"12.9"}]}]},{"title":"Fatigue: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.8","lowerLimit":"0.0","upperLimit":"4.6"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Fatigue: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"3.1"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Headache: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"21.8","lowerLimit":"14.8","upperLimit":"30.4"},{"groupId":"OG001","value":"7.3","lowerLimit":"1.5","upperLimit":"19.9"}]}]},{"title":"Headache: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"10.1","lowerLimit":"5.3","upperLimit":"17.0"},{"groupId":"OG001","value":"7.3","lowerLimit":"1.5","upperLimit":"19.9"}]}]},{"title":"Headache: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.8","lowerLimit":"0.0","upperLimit":"4.6"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Headache: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"3.1"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Chills: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"16.0","lowerLimit":"9.9","upperLimit":"23.8"},{"groupId":"OG001","value":"4.9","lowerLimit":"0.6","upperLimit":"16.5"}]}]},{"title":"Chills: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"8.4","lowerLimit":"4.1","upperLimit":"14.9"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Chills: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.8","lowerLimit":"0.0","upperLimit":"4.6"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Chills: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"3.1"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Vomiting: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"3.1"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Vomiting: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"3.1"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Vomiting: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"3.1"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Vomiting: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"3.1"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Diarrhea: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"3.4","lowerLimit":"0.9","upperLimit":"8.4"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Diarrhea: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"1.7","lowerLimit":"0.2","upperLimit":"5.9"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Diarrhea: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"3.1"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Diarrhea: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"3.1"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"New or worsened muscle pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"10.1","lowerLimit":"5.3","upperLimit":"17.0"},{"groupId":"OG001","value":"2.4","lowerLimit":"0.1","upperLimit":"12.9"}]}]},{"title":"New or worsened muscle pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"4.2","lowerLimit":"1.4","upperLimit":"9.5"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"New or worsened muscle pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"3.1"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"New or worsened muscle pain: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"3.1"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"New or worsened joint pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"9.2","lowerLimit":"4.7","upperLimit":"15.9"},{"groupId":"OG001","value":"4.9","lowerLimit":"0.6","upperLimit":"16.5"}]}]},{"title":"New or worsened joint pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"4.2","lowerLimit":"1.4","upperLimit":"9.5"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"New or worsened joint pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.8","lowerLimit":"0.0","upperLimit":"4.6"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"New or worsened joint pain: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"3.1"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Systemic Events by Maximum Severity Within 7 Days After Dose 2","description":"Systemic events were recorded by participants in an e-diary. Fever was categorized as \\>= 37.5 to 38.4 deg C, \\>38.4 to 38.9 deg C, \\>38.9 to 40.0 deg C and \\>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain were graded as mild: did not interfere with activity, moderate: some interference with activity and severe: prevented daily routine activity. Vomiting was graded as mild: 1 to 2 times in 24h, moderate: \\>2 times in 24h and severe: required intravenous hydration. Diarrhea was graded as mild: 2 to 3 loose stools in 24h, moderate: 4 to 5 loose stools in 24h and severe: 6 or more loose stools in 24h. Events were classified as Grade 4 potentially life threatening (emergency room visit or hospitalization) based on study investigator's judgement. Maximum severity=highest grade within 7 days after vaccination among severity grades where the answers were neither \"no\" nor missing for at least 1 day.","populationDescription":"Safety population included all randomized participants who received at least 1 dose of the study intervention. Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Within 7 days after Dose 2","groups":[{"id":"OG000","title":"BNT162b2","description":"Participants received 2 doses of blinded 30 mcg BNT162b2 vaccine as an intramuscular injection separated by 21 days. Participants were followed up to 12 months after last dose of vaccination."},{"id":"OG001","title":"Placebo","description":"Participants received 2 doses of placebo (normal sterile saline solution) as an intramuscular injection separated by 21 days. Participants were followed up to 12 months after last dose of vaccination."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"116"},{"groupId":"OG001","value":"41"}]}],"classes":[{"title":"Fever: >= 37.5 to 38.4 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"25.0","lowerLimit":"17.4","upperLimit":"33.9"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Fever: >38.4 to 38.9 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"6.9","lowerLimit":"3.0","upperLimit":"13.1"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Fever: >38.9 to 40.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0.9","lowerLimit":"0.0","upperLimit":"4.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Fever: >40.0 deg C","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"3.1"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Fatigue: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"25.9","lowerLimit":"18.2","upperLimit":"34.8"},{"groupId":"OG001","value":"2.4","lowerLimit":"0.1","upperLimit":"12.9"}]}]},{"title":"Fatigue: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"31.0","lowerLimit":"22.8","upperLimit":"40.3"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Fatigue: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"3.4","lowerLimit":"0.9","upperLimit":"8.6"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Fatigue: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"3.1"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Headache: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"25.0","lowerLimit":"17.4","upperLimit":"33.9"},{"groupId":"OG001","value":"7.3","lowerLimit":"1.5","upperLimit":"19.9"}]}]},{"title":"Headache: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"17.2","lowerLimit":"10.9","upperLimit":"25.4"},{"groupId":"OG001","value":"4.9","lowerLimit":"0.6","upperLimit":"16.5"}]}]},{"title":"Headache: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"1.7","lowerLimit":"0.2","upperLimit":"6.1"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Headache: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"3.1"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Chills: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"24.1","lowerLimit":"16.7","upperLimit":"33.0"},{"groupId":"OG001","value":"2.4","lowerLimit":"0.1","upperLimit":"12.9"}]}]},{"title":"Chills: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"19.8","lowerLimit":"13.0","upperLimit":"28.3"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Chills: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"1.7","lowerLimit":"0.2","upperLimit":"6.1"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Chills: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"3.1"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Vomiting: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"0.9","lowerLimit":"0.0","upperLimit":"4.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Vomiting: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"3.1"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Vomiting: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"3.1"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Vomiting: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"3.1"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Diarrhea: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"5.2","lowerLimit":"1.9","upperLimit":"10.9"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Diarrhea: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"3.1"},{"groupId":"OG001","value":"2.4","lowerLimit":"0.1","upperLimit":"12.9"}]}]},{"title":"Diarrhea: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"3.1"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"Diarrhea: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"3.1"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"New or worsened muscle pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"9.5","lowerLimit":"4.8","upperLimit":"16.3"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"New or worsened muscle pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"6.9","lowerLimit":"3.0","upperLimit":"13.1"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"New or worsened muscle pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"3.1"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"New or worsened muscle pain: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"3.1"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"New or worsened joint pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"12.9","lowerLimit":"7.4","upperLimit":"20.4"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"New or worsened joint pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"11.2","lowerLimit":"6.1","upperLimit":"18.4"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"New or worsened joint pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.9","lowerLimit":"0.0","upperLimit":"4.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]},{"title":"New or worsened joint pain: Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"3.1"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"8.6"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Adverse Events (AEs) From Dose 1 up to 1 Month After Dose 2","description":"An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants with AEs and the associated 95% confidence interval (CI) based on the Clopper and Pearson method was presented. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.","populationDescription":"Safety population included all randomized participants who received at least 1 dose of the study intervention.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Dose 1 up to 1 month after Dose 2","groups":[{"id":"OG000","title":"BNT162b2","description":"Participants received 2 doses of blinded 30 mcg BNT162b2 vaccine as an intramuscular injection separated by 21 days. Participants were followed up to 12 months after last dose of vaccination."},{"id":"OG001","title":"Placebo","description":"Participants received 2 doses of placebo (normal sterile saline solution) as an intramuscular injection separated by 21 days. Participants were followed up to 12 months after last dose of vaccination."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"41"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.9","lowerLimit":"5.9","upperLimit":"18.0"},{"groupId":"OG001","value":"7.3","lowerLimit":"1.5","upperLimit":"19.9"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Serious Adverse Events (SAEs) From Dose 1 up to 12 Months After Dose 2","description":"SAE was defined as any untoward medical occurrence that, at any dose, resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect or considered an important medical event. Percentage of participants with SAEs and the associated 95% CI based on the Clopper and Pearson method was presented.","populationDescription":"Safety population included all randomized participants who received at least 1 dose of the study intervention.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Dose 1 up to 12 months after Dose 2","groups":[{"id":"OG000","title":"BNT162b2","description":"Participants received 2 doses of blinded 30 mcg BNT162b2 vaccine as an intramuscular injection separated by 21 days. Participants were followed up to 12 months after last dose of vaccination."},{"id":"OG001","title":"Placebo","description":"Participants received 2 doses of placebo (normal sterile saline solution) as an intramuscular injection separated by 21 days. Participants were followed up to 12 months after last dose of vaccination."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"41"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","lowerLimit":"0.2","upperLimit":"5.9"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"8.6"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Abnormal Hematology and Chemistry Laboratory Values 1 Day After Dose 1 by Age Category","description":"The pre-defined criteria for laboratory parameters included: hemoglobin (HGB), hematocrit, erythrocytes(ery.) less than (\\<)0.8\\* lower limit of normal (LLN); ery. mean corpuscular volume, ery. mean corpuscular hemoglobin, ery. mean corpuscular HGB concentration \\<0.9\\*LLN and \\>1.1\\*upper limit of normal (ULN); platelets \\<0.5\\*LLN and \\>1.75\\*ULN; leukocytes \\<0.6\\*LLN and \\>1.5\\*ULN; lymphocytes, neutrophils \\<0.8\\*LLN and \\>1.2\\*ULN; basophils, eosinophils, monocytes \\>1.2\\*ULN; bilirubin \\>1.5\\*ULN; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase \\>3.0\\*ULN; urea nitrogen, creatinine \\>1.3\\*ULN. Percentage of participants with abnormal hematology and chemistry laboratory values by age categories 20 to 64 years and 65 to 85 years were reported in this outcome measure. Categories with at least 1 non-zero data values were reported.","populationDescription":"Safety population included all randomized participants who received at least 1 dose of the study intervention. Here, \"Overall Number of Participants Analyzed\" signifies participants with at least one result for the laboratory test after study vaccination.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Within 1 day after Dose 1","groups":[{"id":"OG000","title":"BNT162b2","description":"Participants received 2 doses of blinded 30 mcg BNT162b2 vaccine as an intramuscular injection separated by 21 days. Participants were followed up to 12 months after last dose of vaccination."},{"id":"OG001","title":"Placebo","description":"Participants received 2 doses of placebo (normal sterile saline solution) as an intramuscular injection separated by 21 days. Participants were followed up to 12 months after last dose of vaccination."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"3"}]}],"classes":[{"title":"20-64 Years: Monocytes","categories":[{"measurements":[{"groupId":"OG000","value":"11.1"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"65-85 Years: Lymphocytes","categories":[{"measurements":[{"groupId":"OG000","value":"22.2"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"65-85 Years: Monocytes","categories":[{"measurements":[{"groupId":"OG000","value":"11.1"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"65-85 Years: Creatinine","categories":[{"measurements":[{"groupId":"OG000","value":"11.1"},{"groupId":"OG001","value":"0.0"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Abnormal Hematology and Chemistry Laboratory Values 7 Days After Dose 1 by Age Category","description":"The pre-defined criteria for laboratory parameters included: HGB, hematocrit, ery. \\<0.8\\* LLN; ery. mean corpuscular volume, ery. mean corpuscular hemoglobin, ery. mean corpuscular HGB concentration \\<0.9\\*LLN and \\>1.1\\*ULN; platelets \\<0.5\\*LLN and \\>1.75\\*ULN; leukocytes \\<0.6\\*LLN and \\>1.5\\*ULN; lymphocytes, neutrophils \\<0.8\\*LLN and \\>1.2\\*ULN; basophils, eosinophils, monocytes \\>1.2\\*ULN; bilirubin \\>1.5\\*ULN; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase \\>3.0\\*ULN; urea nitrogen, creatinine \\>1.3\\*ULN. Percentage of participants with abnormal hematology and chemistry laboratory values by age categories 20 to 64 years and 65 to 85 years were reported in this outcome measure. Categories with at least 1 non-zero data values were reported.","populationDescription":"Safety population included all randomized participants who received at least 1 dose of the study intervention. Here, \"Overall Number of Participants Analyzed\" signifies participants with at least one result for the laboratory test after study vaccination.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Within 7 days after Dose 1","groups":[{"id":"OG000","title":"BNT162b2","description":"Participants received 2 doses of blinded 30 mcg BNT162b2 vaccine as an intramuscular injection separated by 21 days. Participants were followed up to 12 months after last dose of vaccination."},{"id":"OG001","title":"Placebo","description":"Participants received 2 doses of placebo (normal sterile saline solution) as an intramuscular injection separated by 21 days. Participants were followed up to 12 months after last dose of vaccination."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"3"}]}],"classes":[{"title":"20-64 Years: Eosinophils","categories":[{"measurements":[{"groupId":"OG000","value":"11.1"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"65-85 Years: Lymphocytes","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"33.3"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Abnormal Hematology and Chemistry Laboratory Values 7 Days After Dose 2 by Age Category","description":"The pre-defined criteria for laboratory parameters included: HGB, hematocrit, ery. \\<0.8\\* LLN; ery. mean corpuscular volume, ery. mean corpuscular hemoglobin, ery. mean corpuscular HGB concentration \\<0.9\\*LLN and \\>1.1\\*ULN; platelets \\<0.5\\*LLN and \\>1.75\\*ULN; leukocytes \\<0.6\\*LLN and \\>1.5\\*ULN; lymphocytes, neutrophils \\<0.8\\*LLN and \\>1.2\\*ULN; basophils, eosinophils, monocytes \\>1.2\\*ULN; bilirubin \\>1.5\\*ULN; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase \\>3.0\\*ULN; urea nitrogen, creatinine \\>1.3\\*ULN. Categories with at least 1 non-zero data value were reported (only 65-85 years: Lymphocytes category was reported).","populationDescription":"Safety population included all randomized participants who received at least 1 dose of the study intervention. Here, \"Overall Number of Participants Analyzed\" signifies participants with at least one result for the laboratory test after study vaccination.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Within 7 days after Dose 2","groups":[{"id":"OG000","title":"BNT162b2","description":"Participants received 2 doses of blinded 30 mcg BNT162b2 vaccine as an intramuscular injection separated by 21 days. Participants were followed up to 12 months after last dose of vaccination."},{"id":"OG001","title":"Placebo","description":"Participants received 2 doses of placebo (normal sterile saline solution) as an intramuscular injection separated by 21 days. Participants were followed up to 12 months after last dose of vaccination."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"3"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.2"},{"groupId":"OG001","value":"33.3"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Shift in Hematology and Chemistry Laboratory Values From Baseline to 1 Day After Dose 1 by Age Category","description":"Hematology parameters: hemoglobin, eosinophils, lymphocytes decrease, neutrophil decrease, platelets decrease, white blood cell (WBC) decrease, WBC increase. Chemistry parameters: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, bilirubin increased, creatinine increased, blood urea nitrogen. Laboratory abnormalities were graded by toxicity grading scale for healthy adult volunteers enrolled in preventive vaccine clinical trials as grade 1=mild; grade 2=moderate; grade 3=severe and grade 4=potentially life-threatening. Percentage of participants with shift in hematology and chemistry laboratory values by age categories (20 to 64 years and 65 to 85 years) were reported in this outcome measure. Categories with at least 1 non-zero data values showing any shift in Grade from baseline to 1 day after dose 1 (post-baseline) were reported. Participants whose grade category was unchanged (e.g. normal to normal) were not reported.","populationDescription":"Safety population included all randomized participants who received at least 1 dose of the study intervention. Here, \"Overall Number of Participants Analyzed\" signifies participants with at least 1 result for the laboratory test for both baseline and postvaccination visits.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"From baseline (observation prior to Dose 1) up to 1 day after Dose 1","groups":[{"id":"OG000","title":"BNT162b2","description":"Participants received 2 doses of blinded 30 mcg BNT162b2 vaccine as an intramuscular injection separated by 21 days. Participants were followed up to 12 months after last dose of vaccination."},{"id":"OG001","title":"Placebo","description":"Participants received 2 doses of placebo (normal sterile saline solution) as an intramuscular injection separated by 21 days. Participants were followed up to 12 months after last dose of vaccination."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"3"}]}],"classes":[{"title":"20-64 Years- Lymphocytes: Normal (at baseline) to Grade 1 (at post baseline)","categories":[{"measurements":[{"groupId":"OG000","value":"22.2"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"20-64 Years- Neutrophil Decrease: Normal (at baseline) to Grade 1 (at post baseline)","categories":[{"measurements":[{"groupId":"OG000","value":"55.6"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"20-64 Years- WBC Decrease: Normal (at baseline) to Grade 1 (at post baseline)","categories":[{"measurements":[{"groupId":"OG000","value":"11.1"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"65-85 Years- Alanine Aminotransferase Increased: Normal (at baseline) to Grade 1 (at post baseline)","categories":[{"measurements":[{"groupId":"OG000","value":"11.1"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"65-85 Years-Aspartate Aminotransferase Increased: Normal (at baseline) to Grade 1 (at post baseline)","categories":[{"measurements":[{"groupId":"OG000","value":"11.1"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"65-85 Years- Hemoglobin: Normal (at baseline) to Grade 1 (at post baseline)","categories":[{"measurements":[{"groupId":"OG000","value":"11.1"},{"groupId":"OG001","value":"33.3"}]}]},{"title":"65-85 Years- Lymphocytes: Normal (at baseline) to Grade 1 (at post baseline)","categories":[{"measurements":[{"groupId":"OG000","value":"33.3"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"65-85 Years- Neutrophil Decrease: Normal (at baseline) to Grade 1 (at post baseline)","categories":[{"measurements":[{"groupId":"OG000","value":"22.2"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"65-85 Years- Neutrophil Decrease: Normal (at baseline) to Grade 2 (at post baseline)","categories":[{"measurements":[{"groupId":"OG000","value":"11.1"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"65-85 Years- Urea Nitrogen: Normal (at baseline) to Grade 1 (at post baseline)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"33.3"}]}]},{"title":"65-85 Years- WBC Decrease: Normal (at baseline) to Grade 1 (at post baseline)","categories":[{"measurements":[{"groupId":"OG000","value":"33.3"},{"groupId":"OG001","value":"0.0"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Shift in Hematology and Chemistry Laboratory Values From Baseline to 7 Days After Dose 1 by Age Category","description":"Hematology parameters included: hemoglobin, eosinophils, lymphocytes decrease, neutrophil decrease, platelets decrease, WBC decrease, WBC increase. Chemistry parameters included: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, bilirubin increased, creatinine increased, urea nitrogen. Laboratory abnormalities were graded by toxicity grading scale for healthy adult volunteers enrolled in preventive vaccine clinical trials as grade 1=mild; grade 2=moderate; grade 3=severe and grade 4=potentially life-threatening. Percentage of participants with shift in hematology and chemistry laboratory values by age categories (20 to 64 years and 65 to 85 years) were reported in this outcome measure. Categories with at least 1 non-zero data values showing any shift in grade from baseline to 7 days after dose 1 (post-baseline) were reported. Participants whose grade category was unchanged (e.g. normal to normal) were not reported.","populationDescription":"Safety population included all randomized participants who received at least 1 dose of the study intervention. Here, \"Overall Number of Participants Analyzed\" signifies participants with at least 1 result for the laboratory test for both baseline and postvaccination visits.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"From baseline (observation prior to Dose 1) up to 7 days after Dose 1","groups":[{"id":"OG000","title":"BNT162b2","description":"Participants received 2 doses of blinded 30 mcg BNT162b2 vaccine as an intramuscular injection separated by 21 days. Participants were followed up to 12 months after last dose of vaccination."},{"id":"OG001","title":"Placebo","description":"Participants received 2 doses of placebo (normal sterile saline solution) as an intramuscular injection separated by 21 days. Participants were followed up to 12 months after last dose of vaccination."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"3"}]}],"classes":[{"title":"20-64 Years- Hemoglobin: Normal (at baseline) to Grade 1 (at post baseline)","categories":[{"measurements":[{"groupId":"OG000","value":"11.1"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"20-64 Years- Neutrophil Decrease: Grade 1 (at baseline) to Normal (at post baseline)","categories":[{"measurements":[{"groupId":"OG000","value":"11.1"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"65-85 Years- Alanine Aminotransferase Increased: Normal (at baseline) to Grade 1 (at post baseline)","categories":[{"measurements":[{"groupId":"OG000","value":"11.1"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"65-85 Years-Aspartate Aminotransferase Increased: Normal (at baseline) to Grade 1 (at post baseline)","categories":[{"measurements":[{"groupId":"OG000","value":"11.1"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"65-85 Years- Hemoglobin: Normal (at baseline) to Grade 1 (at post baseline)","categories":[{"measurements":[{"groupId":"OG000","value":"11.1"},{"groupId":"OG001","value":"33.3"}]}]},{"title":"65-85 Years- Hemoglobin: Grade 1 (at baseline) to Grade 2 (at post baseline)","categories":[{"measurements":[{"groupId":"OG000","value":"11.1"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"65-85 Years- Lymphocytes: Normal (at baseline) to Grade 1 (at post baseline)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"33.3"}]}]},{"title":"65-85 Years- WBC Decrease: Normal (at baseline) to Grade 1 (at post baseline)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"33.3"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Shift in Hematology and Chemistry Laboratory Values From Before Dose 2 to 7 Days After Dose 2 by Age Category","description":"Hematology parameters included: hemoglobin, eosinophils, lymphocytes decrease, neutrophil decrease, platelets decrease, WBC decrease, WBC increase. Chemistry parameters included: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, bilirubin increased, creatinine increased, urea nitrogen. Laboratory abnormalities were graded by toxicity grading scale for healthy adult volunteers enrolled in preventive vaccine clinical trials as grade 1=mild; grade 2=moderate; grade 3= severe and grade 4=potentially life-threatening. Percentage of participants with shift in hematology and chemistry laboratory values by age categories (20 to 64 years and 65 to 85 years) were reported in this outcome measure. Categories with at least 1 non-zero data values showing any shift in grade from before dose 2 to 7 days after dose 2 were reported. Participants whose grade category was unchanged (e.g. normal to normal) were not reported.","populationDescription":"Safety population included all randomized participants who received at least 1 dose of the study intervention. Here, \"Overall Number of Participants Analyzed\" signifies participants with at least 1 result for the laboratory test for both baseline and postvaccination visits.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Before Dose 2 up to 7 days after Dose 2","groups":[{"id":"OG000","title":"BNT162b2","description":"Participants received 2 doses of blinded 30 mcg BNT162b2 vaccine as an intramuscular injection separated by 21 days. Participants were followed up to 12 months after last dose of vaccination."},{"id":"OG001","title":"Placebo","description":"Participants received 2 doses of placebo (normal sterile saline solution) as an intramuscular injection separated by 21 days. Participants were followed up to 12 months after last dose of vaccination."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"3"}]}],"classes":[{"title":"20-64 Years- Alanine Aminotransferase Increased: Grade 1 (before dose 2) to Normal (post dose 2)","categories":[{"measurements":[{"groupId":"OG000","value":"11.1"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"20-64 Years- Eosinophils: Grade 1 (before dose 2) to Normal (post dose 2)","categories":[{"measurements":[{"groupId":"OG000","value":"11.1"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"20-64 Years- Hemoglobin: Normal (before dose 2) to Grade 1 (post dose 2)","categories":[{"measurements":[{"groupId":"OG000","value":"11.1"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"20-64 Years- Hemoglobin: Grade 1 (before dose 2) to Normal (post dose 2)","categories":[{"measurements":[{"groupId":"OG000","value":"11.1"},{"groupId":"OG001","value":"33.3"}]}]},{"title":"20-64 Years- Neutrophil Decrease: Grade 1 (before dose 2) to Normal (post dose 2)","categories":[{"measurements":[{"groupId":"OG000","value":"22.2"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"20-64 Years- WBC Decrease: Grade 1 (before dose 2) to Normal (post dose 2)","categories":[{"measurements":[{"groupId":"OG000","value":"11.1"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"65-85 Years-Aspartate Aminotransferase Increased: Normal (before dose 2) to Grade 1 (post dose 2)","categories":[{"measurements":[{"groupId":"OG000","value":"11.1"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"65-85 Years- Bilirubin: Grade 1 (before dose 2) to Normal (post dose 2)","categories":[{"measurements":[{"groupId":"OG000","value":"11.1"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"65-85 Years- Hemoglobin: Normal (before dose 2) to Grade 1 (post dose 2)","categories":[{"measurements":[{"groupId":"OG000","value":"11.1"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"65-85 Years- Hemoglobin: Grade 1 (before dose 2) to Grade 2 (post dose 2)","categories":[{"measurements":[{"groupId":"OG000","value":"11.1"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"65-85 Years- Lymphocytes: Normal (before dose 2) to Grade 1 (post dose 2)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"33.3"}]}]},{"title":"65-85 Years- Neutrophil Decrease: Normal (before dose 2) to Grade 1 (post dose 2)","categories":[{"measurements":[{"groupId":"OG000","value":"22.2"},{"groupId":"OG001","value":"33.3"}]}]},{"title":"65-85 Years- Urea Nitrogen: Normal (before dose 2) to Grade 1 (post dose 2)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"33.3"}]}]},{"title":"65-85 Years- WBC Decrease: Normal (before dose 2) to Grade 1 (post dose 2)","categories":[{"measurements":[{"groupId":"OG000","value":"11.1"},{"groupId":"OG001","value":"33.3"}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titers (GMTs) of SARS-CoV-2 Neutralizing Titers at 1 Month After Dose 2","description":"GMT of SARS-CoV-2 neutralizing titer was calculated by exponentiating the mean logarithm of the titers and the corresponding 95% confidence interval (CI) was based on the Student's t distribution. GMT of SARS-CoV-2 neutralization titer 50% (NT50) was reported in this outcome measure.","populationDescription":"Evaluable immunogenicity population (EIP): all randomized participants who received 2 doses of the assigned vaccine, with Dose 2 received within the predefined window (within 19-42 days after Dose 1), had at least 1 valid and determinate immunogenicity result from the blood collection within an appropriate window after Dose 2 (within 28-42 days after Dose 2) and had no other major protocol deviations as determined by clinician.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"1 month after Dose 2","groups":[{"id":"OG000","title":"BNT162b2","description":"Participants received 2 doses of blinded 30 mcg BNT162b2 vaccine as an intramuscular injection separated by 21 days. Participants were followed up to 12 months after last dose of vaccination."},{"id":"OG001","title":"Placebo","description":"Participants received 2 doses of placebo (normal sterile saline solution) as an intramuscular injection separated by 21 days. Participants were followed up to 12 months after last dose of vaccination."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"116"},{"groupId":"OG001","value":"41"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"524.5","lowerLimit":"459.7","upperLimit":"598.4"},{"groupId":"OG001","value":"10.6","lowerLimit":"9.8","upperLimit":"11.4"}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Fold Rises (GMFRs) of SARS-CoV-2 Neutralizing Titers From Before Vaccination to 1 Month After Dose 2","description":"GMFR was defined as the result after vaccination divided by the result before vaccination. GMFR and the corresponding 2-sided 95% CIs was calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student's t distribution). GMFR of SARS-CoV-2 NT50 was reported in this outcome measure.","populationDescription":"EIP: all randomized participants who received 2 doses of the assigned vaccine, with Dose 2 received within the predefined window (within 19-42 days after Dose 1), had at least 1 valid and determinate immunogenicity result from the blood collection within an appropriate window after Dose 2 (within 28-42 days after Dose 2) and had no other major protocol deviations as determined by clinician.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Fold rise","timeFrame":"Before vaccination up to 1 month after Dose 2","groups":[{"id":"OG000","title":"BNT162b2","description":"Participants received 2 doses of blinded 30 mcg BNT162b2 vaccine as an intramuscular injection separated by 21 days. Participants were followed up to 12 months after last dose of vaccination."},{"id":"OG001","title":"Placebo","description":"Participants received 2 doses of placebo (normal sterile saline solution) as an intramuscular injection separated by 21 days. Participants were followed up to 12 months after last dose of vaccination."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"116"},{"groupId":"OG001","value":"41"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.5","lowerLimit":"45.2","upperLimit":"58.7"},{"groupId":"OG001","value":"1.1","lowerLimit":"1.0","upperLimit":"1.1"}]}]}]},{"type":"SECONDARY","title":"GMTs of SARS-CoV-2 Neutralizing Titers at Baseline, 21 Days After Dose 1; 7 and 14 Days and 6 and 12 Months After Dose 2","description":"GMTs of SARS-CoV-2 neutralizing titers were calculated by exponentiating the mean logarithm of the titers and the corresponding 95% CI was based on the Student's t distribution. GMTs of SARS-CoV-2 NT50 and neutralization titer 90% (NT90) were reported in this outcome measure.","populationDescription":"EIP: all randomized participants who received 2 doses of the assigned vaccine, with Dose 2 received within the predefined window (within 19-42 days after Dose 1), had at least 1 valid and determinate immunogenicity result from the blood collection within an appropriate window after Dose 2 (within 28-42 days after Dose 2) and had no other major protocol deviations as determined by clinician. \"Number Analyzed\" signifies participants evaluable for this outcome measure at specified time points.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"NT50: Baseline (observation prior to Dose 1), 21 days after Dose 1; 7 and 14 days and 6 and 12 months after Dose 2; NT90: Baseline (observation prior to Dose 1), 21 days after Dose 1; 7 and 14 days after Dose 2","groups":[{"id":"OG000","title":"BNT162b2","description":"Participants received 2 doses of blinded 30 mcg BNT162b2 vaccine as an intramuscular injection separated by 21 days. Participants were followed up to 12 months after last dose of vaccination."},{"id":"OG001","title":"Placebo","description":"Participants received 2 doses of placebo (normal sterile saline solution) as an intramuscular injection separated by 21 days. Participants were followed up to 12 months after last dose of vaccination."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"116"},{"groupId":"OG001","value":"41"}]}],"classes":[{"title":"NT50: Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"116"},{"groupId":"OG001","value":"41"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.2","lowerLimit":"9.8","upperLimit":"10.6"},{"groupId":"OG001","value":"10.0","lowerLimit":"10.0","upperLimit":"10.0"}]}]},{"title":"NT50: 21 days after Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"116"},{"groupId":"OG001","value":"40"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"29.2","lowerLimit":"24.3","upperLimit":"35.2"},{"groupId":"OG001","value":"10.0","lowerLimit":"10.0","upperLimit":"10.0"}]}]},{"title":"NT50: 7 days after Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"116"},{"groupId":"OG001","value":"41"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"408.2","lowerLimit":"352.0","upperLimit":"473.3"},{"groupId":"OG001","value":"10.0","lowerLimit":"10.0","upperLimit":"10.0"}]}]},{"title":"NT50: 14 days after Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"116"},{"groupId":"OG001","value":"41"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"379.4","lowerLimit":"335.3","upperLimit":"429.3"},{"groupId":"OG001","value":"10.0","lowerLimit":"10.0","upperLimit":"10.0"}]}]},{"title":"NT50: 6 months after Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"116"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"145.6","lowerLimit":"126.1","upperLimit":"168.2"},{"groupId":"OG001","value":"20.5","lowerLimit":"20.5","upperLimit":"20.5"}]}]},{"title":"NT50: 12 months after Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"115"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"74.2","lowerLimit":"59.6","upperLimit":"92.3"},{"groupId":"OG001","value":"63.8","lowerLimit":"0.5","upperLimit":"8440.7"}]}]},{"title":"NT90: Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"116"},{"groupId":"OG001","value":"41"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.1","lowerLimit":"9.9","upperLimit":"10.2"},{"groupId":"OG001","value":"10.0","lowerLimit":"10.0","upperLimit":"10.0"}]}]},{"title":"NT90: 21 days after Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"116"},{"groupId":"OG001","value":"40"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.4","lowerLimit":"10.5","upperLimit":"12.5"},{"groupId":"OG001","value":"10.0","lowerLimit":"10.0","upperLimit":"10.0"}]}]},{"title":"NT90: 7 days after Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"116"},{"groupId":"OG001","value":"41"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"104.3","lowerLimit":"90.1","upperLimit":"120.7"},{"groupId":"OG001","value":"10.0","lowerLimit":"10.0","upperLimit":"10.0"}]}]},{"title":"NT90: 14 days after Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"116"},{"groupId":"OG001","value":"41"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"95.8","lowerLimit":"84.8","upperLimit":"108.2"},{"groupId":"OG001","value":"10.0","lowerLimit":"10.0","upperLimit":"10.0"}]}]}]},{"type":"SECONDARY","title":"GMFRs of SARS-CoV-2 Neutralizing Titers Before Vaccination to 21 Days After Dose 1; 7 and 14 Days and 6 and 12 Months After Dose 2","description":"GMFR was defined as the result after vaccination divided by the result before vaccination. GMFRs and the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student's t distribution). GMFRs of SARS-CoV-2 NT50 and NT90 were reported in this outcome measure.","populationDescription":"EIP: all randomized participants who received 2 doses of the assigned vaccine, with Dose 2 received within the predefined window (within 19-42 days after Dose 1), had at least 1 valid and determinate immunogenicity result from the blood collection within an appropriate window after Dose 2 (within 28-42 days after Dose 2) and had no other major protocol deviations as determined by clinician. \"Number Analyzed\" signifies participants evaluable for this outcome measure at specified time points.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Fold rise","timeFrame":"NT50: Before vaccination up to 21 days after Dose 1; 7 and 14 days and 6 and 12 months after Dose 2; NT90: Before vaccination up to 21 days after Dose 1; 7 and 14 days after Dose 2","groups":[{"id":"OG000","title":"BNT162b2","description":"Participants received 2 doses of blinded 30 mcg BNT162b2 vaccine as an intramuscular injection separated by 21 days. Participants were followed up to 12 months after last dose of vaccination."},{"id":"OG001","title":"Placebo","description":"Participants received 2 doses of placebo (normal sterile saline solution) as an intramuscular injection separated by 21 days. Participants were followed up to 12 months after last dose of vaccination."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"116"},{"groupId":"OG001","value":"41"}]}],"classes":[{"title":"NT50: before vaccination up to 21 days after Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"116"},{"groupId":"OG001","value":"40"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","lowerLimit":"2.4","upperLimit":"3.4"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"NT50: before vaccination up to 7 days after Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"116"},{"groupId":"OG001","value":"41"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"40.1","lowerLimit":"34.6","upperLimit":"46.5"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"NT50: before vaccination up to 14 days after Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"116"},{"groupId":"OG001","value":"41"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"37.2","lowerLimit":"32.9","upperLimit":"42.1"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"NT50: before vaccination up to 6 months after Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"116"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14.3","lowerLimit":"12.4","upperLimit":"16.5"},{"groupId":"OG001","value":"2.1","lowerLimit":"2.1","upperLimit":"2.1"}]}]},{"title":"NT50: before vaccination up to 12 months after Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"115"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.3","lowerLimit":"5.9","upperLimit":"9.1"},{"groupId":"OG001","value":"6.4","lowerLimit":"0.0","upperLimit":"844.1"}]}]},{"title":"NT90: before vaccination up to 21 days after Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"116"},{"groupId":"OG001","value":"40"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","lowerLimit":"1.1","upperLimit":"1.2"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"NT90: before vaccination up to 7 days after Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"116"},{"groupId":"OG001","value":"41"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.3","lowerLimit":"8.9","upperLimit":"12.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"NT90: before vaccination up to 14 days after Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"116"},{"groupId":"OG001","value":"41"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.5","lowerLimit":"8.4","upperLimit":"10.7"},{"groupId":"OG001","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]}]},{"type":"SECONDARY","title":"GMTs of SARS-CoV-2 Neutralizing Titers at Baseline, 21 Days After Dose 1; 7 and 14 Days and 1, 6 and 12 Months After Dose 2 in Participants With or Without Confirmed COVID-19 Before Dose 2","description":"GMTs of SARS-CoV-2 neutralizing titers was planned to be calculated by exponentiating the mean logarithm of the titers and the corresponding 95% CI was based on the Student's t distribution.","populationDescription":"Data was not analyzed as there were no participants with or without confirmed COVID-19 before Dose 2 prior to unblinding.","reportingStatus":"POSTED","timeFrame":"Baseline (observation prior to Dose 1), 21 days after Dose 1; 7 and 14 days and 1, 6 and 12 months after Dose 2","groups":[{"id":"OG000","title":"BNT162b2","description":"Participants received 2 doses of blinded 30 mcg BNT162b2 vaccine as an intramuscular injection separated by 21 days. Participants were followed up to 12 months after last dose of vaccination."},{"id":"OG001","title":"Placebo","description":"Participants received 2 doses of placebo (normal sterile saline solution) as an intramuscular injection separated by 21 days. Participants were followed up to 12 months after last dose of vaccination."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"type":"SECONDARY","title":"GMFRs of SARS-CoV-2 Neutralizing Titers Before Vaccination to 21 Days After Dose 1; 7 and 14 Days and 1, 6 and 12 Months After Dose 2 in Participants With or Without Confirmed COVID-19 Before Dose 2","description":"GMFR was defined as the result after vaccination divided by the result before vaccination. GMFRs and the corresponding 2-sided 95% CIs were planned to be calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student's t distribution).","populationDescription":"Data was not analyzed as there were no participants with or without confirmed COVID-19 before Dose 2 prior to unblinding.","reportingStatus":"POSTED","timeFrame":"Before vaccination up to 21 days after Dose 1; 7 and 14 days after Dose 2 and 1, 6 and 12 months after Dose 2","groups":[{"id":"OG000","title":"BNT162b2","description":"Participants received 2 doses of blinded 30 mcg BNT162b2 vaccine as an intramuscular injection separated by 21 days. Participants were followed up to 12 months after last dose of vaccination."},{"id":"OG001","title":"Placebo","description":"Participants received 2 doses of placebo (normal sterile saline solution) as an intramuscular injection separated by 21 days. Participants were followed up to 12 months after last dose of vaccination."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},"adverseEventsModule":{"frequencyThreshold":"1","timeFrame":"Local reactions/systemic events: within 7 days after each dose; SAEs: from Dose 1 up to 12 months after Dose 2 except for Placebo Then BNT162b2 reporting arm; SAEs for Placebo Then BNT162b2 reporting arm: from Dose 3 up to 6 months after Dose 4: other AEs: from Dose 1 up to 1 month after Dose 2 for BNT162b2 and Placebo arms; from Dose 3 up to 1 month after Dose 4 for Placebo Then BNT162b2 reporting arm.","description":"Same event may appear as both an AE and SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both a serious and non-serious event. Systematic events include local reactions and systemic events recorded by participants in e-diary and non-systematic events include all other AEs.","eventGroups":[{"id":"EG000","title":"BNT162b2","description":"Participants received 2 doses of blinded 30 mcg BNT162b2 vaccine as an intramuscular injection separated by 21 days. Participants were followed up to 12 months after last dose of vaccination.","deathsNumAffected":0,"deathsNumAtRisk":119,"seriousNumAffected":2,"seriousNumAtRisk":119,"otherNumAffected":111,"otherNumAtRisk":119},{"id":"EG001","title":"Placebo","description":"Participants received 2 doses of placebo (normal sterile saline solution) as an intramuscular injection separated by 21 days. Participants were followed up to 12 months after last dose of vaccination.","deathsNumAffected":0,"deathsNumAtRisk":41,"seriousNumAffected":0,"seriousNumAtRisk":41,"otherNumAffected":12,"otherNumAtRisk":41},{"id":"EG002","title":"Placebo Then BNT162b2","description":"Participants who originally received 2 doses of blinded placebo were administered 2 doses of 30 mcg BNT162b2 vaccine as intramuscular injection separated by 21 days after unblinding. Participants were followed for up to 6 months after last dose of vaccination.","deathsNumAffected":0,"deathsNumAtRisk":35,"seriousNumAffected":0,"seriousNumAtRisk":35,"otherNumAffected":31,"otherNumAtRisk":35}],"seriousEvents":[{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":119},{"groupId":"EG001","numAffected":0,"numAtRisk":41},{"groupId":"EG002","numAffected":0,"numAtRisk":35}]},{"term":"Ovarian neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":119},{"groupId":"EG001","numAffected":0,"numAtRisk":41},{"groupId":"EG002","numAffected":0,"numAtRisk":35}]}],"otherEvents":[{"term":"Diarrhoea (DIARRHEA)","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":119},{"groupId":"EG001","numAffected":1,"numAtRisk":41},{"groupId":"EG002","numAffected":0,"numAtRisk":35}]},{"term":"Chills (CHILLS)","organSystem":"General disorders","sourceVocabulary":"MedDRA v24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":58,"numAtRisk":119},{"groupId":"EG001","numAffected":3,"numAtRisk":41},{"groupId":"EG002","numAffected":0,"numAtRisk":35}]},{"term":"Fatigue (FATIGUE)","organSystem":"General disorders","sourceVocabulary":"MedDRA v24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":75,"numAtRisk":119},{"groupId":"EG001","numAffected":4,"numAtRisk":41},{"groupId":"EG002","numAffected":0,"numAtRisk":35}]},{"term":"Injection site erythema (REDNESS)","organSystem":"General disorders","sourceVocabulary":"MedDRA v24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":23,"numAtRisk":119},{"groupId":"EG001","numAffected":0,"numAtRisk":41},{"groupId":"EG002","numAffected":0,"numAtRisk":35}]},{"term":"Injection site pain (PAIN)","organSystem":"General disorders","sourceVocabulary":"MedDRA v24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":109,"numAtRisk":119},{"groupId":"EG001","numAffected":1,"numAtRisk":41},{"groupId":"EG002","numAffected":0,"numAtRisk":35}]},{"term":"Injection site swelling (SWELLING)","organSystem":"General disorders","sourceVocabulary":"MedDRA v24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":119},{"groupId":"EG001","numAffected":0,"numAtRisk":41},{"groupId":"EG002","numAffected":0,"numAtRisk":35}]},{"term":"Pyrexia (FEVER)","organSystem":"General disorders","sourceVocabulary":"MedDRA v24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":43,"numAtRisk":119},{"groupId":"EG001","numAffected":0,"numAtRisk":41},{"groupId":"EG002","numAffected":0,"numAtRisk":35}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA v24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":119},{"groupId":"EG001","numAffected":1,"numAtRisk":41},{"groupId":"EG002","numAffected":16,"numAtRisk":35}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":119},{"groupId":"EG001","numAffected":1,"numAtRisk":41},{"groupId":"EG002","numAffected":0,"numAtRisk":35}]},{"term":"Arthralgia (JOINT PAIN)","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":35,"numAtRisk":119},{"groupId":"EG001","numAffected":2,"numAtRisk":41},{"groupId":"EG002","numAffected":0,"numAtRisk":35}]},{"term":"Myalgia (MUSCLE PAIN)","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":29,"numAtRisk":119},{"groupId":"EG001","numAffected":1,"numAtRisk":41},{"groupId":"EG002","numAffected":0,"numAtRisk":35}]},{"term":"Headache (HEADACHE)","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":64,"numAtRisk":119},{"groupId":"EG001","numAffected":8,"numAtRisk":41},{"groupId":"EG002","numAffected":0,"numAtRisk":35}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":119},{"groupId":"EG001","numAffected":1,"numAtRisk":41},{"groupId":"EG002","numAffected":17,"numAtRisk":35}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":119},{"groupId":"EG001","numAffected":1,"numAtRisk":41},{"groupId":"EG002","numAffected":0,"numAtRisk":35}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":119},{"groupId":"EG001","numAffected":1,"numAtRisk":41},{"groupId":"EG002","numAffected":0,"numAtRisk":35}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":119},{"groupId":"EG001","numAffected":0,"numAtRisk":41},{"groupId":"EG002","numAffected":1,"numAtRisk":35}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":119},{"groupId":"EG001","numAffected":0,"numAtRisk":41},{"groupId":"EG002","numAffected":1,"numAtRisk":35}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":119},{"groupId":"EG001","numAffected":0,"numAtRisk":41},{"groupId":"EG002","numAffected":3,"numAtRisk":35}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA v24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":119},{"groupId":"EG001","numAffected":0,"numAtRisk":41},{"groupId":"EG002","numAffected":11,"numAtRisk":35}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA v24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":119},{"groupId":"EG001","numAffected":0,"numAtRisk":41},{"groupId":"EG002","numAffected":21,"numAtRisk":35}]},{"term":"Injection site erythema","organSystem":"General disorders","sourceVocabulary":"MedDRA v24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":119},{"groupId":"EG001","numAffected":0,"numAtRisk":41},{"groupId":"EG002","numAffected":1,"numAtRisk":35}]},{"term":"Injection site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA v24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":119},{"groupId":"EG001","numAffected":0,"numAtRisk":41},{"groupId":"EG002","numAffected":31,"numAtRisk":35}]},{"term":"Injection site pruritus","organSystem":"General disorders","sourceVocabulary":"MedDRA v24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":119},{"groupId":"EG001","numAffected":0,"numAtRisk":41},{"groupId":"EG002","numAffected":1,"numAtRisk":35}]},{"term":"Injection site swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA v24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":119},{"groupId":"EG001","numAffected":0,"numAtRisk":41},{"groupId":"EG002","numAffected":2,"numAtRisk":35}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":119},{"groupId":"EG001","numAffected":0,"numAtRisk":41},{"groupId":"EG002","numAffected":13,"numAtRisk":35}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":119},{"groupId":"EG001","numAffected":0,"numAtRisk":41},{"groupId":"EG002","numAffected":7,"numAtRisk":35}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":119},{"groupId":"EG001","numAffected":0,"numAtRisk":41},{"groupId":"EG002","numAffected":1,"numAtRisk":35}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"PIs and respective trial sites shall not publish or refer to in writing or orally, in whole or in part, any data, information or materials generated from the study and the services, without the prior written consent of the sponsor."},"pointOfContact":{"title":"BioNTech clinical trials patient information","organization":"BioNTech SE","email":"patients@biontech.de","phone":"+49 6131 9084","phoneExt":"0"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2021-03-17","uploadDate":"2022-11-22T12:22","filename":"Prot_000.pdf","size":2190773},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2021-11-18","uploadDate":"2022-11-22T12:22","filename":"SAP_001.pdf","size":1894952}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09","submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2022-12-20","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"D000086382","term":"COVID-19"}],"ancestors":[{"id":"D011024","term":"Pneumonia, Viral"},{"id":"D011014","term":"Pneumonia"},{"id":"D012141","term":"Respiratory Tract Infections"},{"id":"D007239","term":"Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D018352","term":"Coronavirus Infections"},{"id":"D003333","term":"Coronaviridae Infections"},{"id":"D030341","term":"Nidovirales Infections"},{"id":"D012327","term":"RNA Virus Infections"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000090982","term":"BNT162 Vaccine"}],"ancestors":[{"id":"D000087503","term":"mRNA Vaccines"},{"id":"D000087504","term":"Nucleic Acid-Based Vaccines"},{"id":"D014614","term":"Vaccines, Synthetic"},{"id":"D011994","term":"Recombinant Proteins"},{"id":"D011506","term":"Proteins"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D014612","term":"Vaccines"},{"id":"D001688","term":"Biological Products"},{"id":"D045424","term":"Complex Mixtures"},{"id":"D000086663","term":"COVID-19 Vaccines"},{"id":"D014765","term":"Viral Vaccines"},{"id":"D000941","term":"Antigens"},{"id":"D001685","term":"Biological Factors"}]}},"hasResults":true}